Viking Therapeutics, Inc. (VKTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Viking Therapeutics (VKTX) Q3 2025: R&D Spend Quadruples as Phase III Obesity Enrollment Accelerates
  October 23, 2025
• Viking Therapeutics (VKTX) Q2 2025: R&D Spend Surges 153% as VK2735 Obesity Pipeline Accelerates
  July 23, 2025
• Viking Therapeutics (VKTX) Q1 2025: R&D Spend Jumps 72% as VK2735 Obesity Program Scales to Phase III
  July 04, 2025

Browse all companies